Crossmark

The combination of anti-PD-1 antibodies, trastuzumab and chemotherapy may improve the outcome of some patients with HER2-positive alpha-fetoprotein-producing gastric cancer: a retrospective real-world analysis from a single center

Crossref DOI link: https://doi.org/10.1186/s12885-025-14808-3

Published Online: 2025-10-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ge, Shaohua

Wang, Feixue

Li, Hongli

Yang, Yuchong

Zhang, Le

Duan, Jingjing

Bai, Ming

Liu, Rui

Ning, Tao

Wang, Xia

Ji, Zhi

Sun, Yansha

Deng, Ting
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82103677, 82072664)

Bethune Charitable Foundation (J202301E034)
License Information

Text and Data Mining valid from 2025-10-10

Version of Record valid from 2025-10-10
More Information

Article History

Received: 7 September 2024

Accepted: 4 August 2025

First Online: 10 October 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below